Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Investor Presentation (November 2022)
33 slides from Jubilant Pharmova's investor presentation, November 2022
Slide 1: Investors Presentation November 2022
Investors Presentation November 2022
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Jubilant Pharmova Limited – Overview
Jubilant Pharmova Limited – Overview Jubilant Pharmova Limited FY22 Revenue Split Segment Wise Region Wise 100% China and ROW India CRDMO 7% 5% Jubilant Pharma Limited 16% Europe & Japan Specialty 7% 100% Pharmaceuticals 43% Jubilant Biosys Limited Generics 19.0% 100% Jubilant Therapeutics India Lim
Slide 4: Jubilant Pharmova – Business Snapshot
Jubilant Pharmova – Business Snapshot Pharmaceuticals Contract Research, Development and Manufacturing Specialty Pharmaceuticals Organisation 1 1 #3 radiopharmaceutical manufacturer in the US 1 Fully integrated Drug Discovery services provider Drug Radio Manufacturing facility based in Montrea
Slide 5: High-Quality, World-Class, Low Cost Manufacturing Footprint and Operational Facilities
High-Quality, World-Class, Low Cost Manufacturing Footprint and Operational Facilities Biosys Gr. Noida Facility Spokane, Washington, USA Contract manufacturing of Sterile injectable and Allergy therapy Roorkee, Uttarakhand Generics manufacturing Noida Montreal, Canada Corporate Office Contrac
Slide 6: Experienced Management Team with High Standards of Corporate Governance
Experienced Management Team with High Standards of Corporate Governance Shyam S Bhartia Hari S Bhartia Chairman Co-Chairman & Managing Director 43 industry years in pharmaceutical, specialty 37 industry years in pharmaceutical, specialty chemicals, foods, oil and gas, aerospace and IT chemicals, foo
Slide 7: Pharmaceuticals Business - Jubilant Pharma
Pharmaceuticals Business - Jubilant Pharma
Slide 8: Pharmaceuticals Business Structure and Evolution: Strong M&A track record
Pharmaceuticals Business Structure and Evolution: Strong M&A track record FY03 FY04 FY05 FY06 FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY21 JLL acquired API Acquired Created R&D Acquired a majority Acquired Acquired Draxis Commissioned Acquired Consolidation of Completed JPL enter
Slide 9: Each of the businesses operate in growing markets with considerable headroom for growth
Each of the 6 businesses operate in growing markets with considerable headroom for growth Market Growth Segments Business Units Market Dynamics Size, $Bn Outlook High barriers to entry (complex manufacturing, customer Specialty Radio- stickiness, and stringent regulations) and limited price 6-8% Pha
Slide 10: Each of the six businesses are at different stages of evolution
Each of the six businesses are at different stages of evolution Stages of Evolution Sustain Momentum Scale-up Turnaround Maintain growth rates and protect Leverage robust platforms and market Restructure for profitability margins to generate cash tailwinds to drive profitable growth Radiopharmaceuti
Slide 11: Looking ahead, markers are in place for sustained/accelerated growth across portfolio
Looking ahead, markers are in place for sustained/accelerated growth across portfolio Stages of Evolution Sustain Momentum Scale-up Turnaround Maintain growth rates and protect Leverage robust platforms and market Restructure for profitability margins to generate cash tailwinds to drive profitable g
Slide 12: Sustained out-performance to be driven by five key differentiators
Sustained out-performance to be driven by five key differentiators • Businesses with different market dynamics and stage of evolution 1 • US-centric front-end and manufacturing help drive innovation and is supported by robust operations from India 1 2 • Specialty businesses have leadership in the US
Slide 13: Business Overview
i <= __ Business Overvi
Slide 14: Radiopharmaceuticals – Innate benefits & R&D potentials
Radiopharmaceuticals – Innate benefits & R&D potentials #3 radiopharmaceutical manufacturer in the US Current status and rank Manufacturing facility based in Montreal Canada High barriers to entry (complex manufacturing, customer stickiness, and stringent regulations) and limited price erosi
Slide 15: Radiopharmaceuticals – Business Overview
Radiopharmaceuticals – Business Overview Uncompromised Quality Innovation Leadership • Founded in 1955, acquired by Jubilant Pharma in 2008 • The essence of Jubilant Radiopharma is a • #3 radiopharmaceutical manufacturer in commitment to the highest quality. Our the US based on revenue • Headquarter
Slide 16: Radiopharmacies – Business Overview
Radiopharmacies – Business Overview # 2 commercial radiopharmacy network in the US Facilities also include three operational cyclotrons Multi-year agreements with GPOs in place 48 SPECT radiopharmacies spread across 22 states Access to 13 PET radiopharmacies via SOFIE 800+ employees c.2.8 mn+
Slide 17: Allergy Immunotherapy (AIT) – Business Overview
Allergy Immunotherapy (AIT) – Business Overview Products Product range includes portfolio of 100+ different allergenic extracts, six insect venom products and exclusive skin diagnostic testing devices #2 player in the allergenic SCIT extract market in the US and the sole supplier for venom immun
Slide 18: CDMO Sterile Injectables – Business Overview
CDMO Sterile Injectables – Business Overview Overview CMO Services across product segments Sterile injectables accounts for 80% CMO revenue while non-sterile products account for the Full suite of services to our customers including supply chain support, balance 20% CMO revenue lab testing service
Slide 19: Generics – Business Overview
Generics – Business Overview Overview Market leader in the US in select products(1) Capabilities in multiple dosage forms Vertical integration via our APIs business Supported by in-house R&D facilities for formulation development Broad therapeutic areas covered include Cardiovascular Syste
Slide 20: Contract Research & Development Services - Business Overview
Contract Research & Development Services - Business Overview Overview Discovery Services up to IND & GMP Provides new Drug Discovery services to global innovators in US, EU, Full suite of services to our customers including supply chain support, lab testing services and project management Japan & A
Slide 21: CDMO - API – Business Overview
CDMO - API – Business Overview Highlights • Over 50% API sales are to regulated markets, resulting in high customer retention levels • 75–80% sales to third-party customers and balance to internal generics business • ~80% of the commercialized portfolio is in lifestyle-disease-related therapeutic ar
Slide 22: Jubilant Therapeutics: Clinical stage precision therapeutics company addressing significant unmet medical needs in oncology and autoimmune d
Jubilant Therapeutics: Clinical stage precision therapeutics company addressing significant unmet medical needs in oncology and autoimmune diseases 22
Slide 23: Jubilant Therapeutics: Differentiated portfolio in oncology & autoimmune diseases
Jubilant Therapeutics: Differentiated portfolio in oncology & autoimmune diseases 23
Slide 24: Jubilant Pharmova - Financials
Jubilant Pharmova - Financials
Slide 25: Financial Performance | P&L
Financial Performance | P&L Revenue from Operations Revenue by Segment 6,130 15% 16% 14% 20% 5,790 24% 19% 23% 11% (Rs Crore) 22% 18% 3,292 23% 24% 3,051 43% 50% 38% 39% FY21 FY22 H1 FY22 H1 FY23 FY21 FY22 H1 FY22 H1 FY23 Specialty Pharma CDMO Sterile Injectables Generics CRDMO EBITDA Normalised PAT
Slide 26: Financial Performance | Balance Sheet
Financial Performance | Balance Sheet Return On Capital Employed (ROCE) Leverage Net Debt/ EBITDA 1.36x 1.67x 14.8% (% age) 2,938 (Rs Crore) 10.5% 2,600 1,928 1,954 FY21 FY22 FY21 FY22 Gross Debt Net Debt Capital Expenditures Working Capital 4.5% 7.1% 86 96 437 1,615 (Rs Crore) (Rs Crore) 276 1,429
Slide 27: Financial Performance | Q2’FY23
Financial Performance | Q2’FY23 Revenues were at Rs 1,600 Crore vs. Rs 1,657 Crore in Q2'FY22 and Rs 1,452 Crore in Q1’FY23. The higher volumes in Radiopharma, Allergy and CDMO Sterile injectables, API and steady growth in Drug Discovery Services led to sequential revenue growth Reported EBITD
Slide 28: Financial Performance | H1’FY23
Financial Performance | H1’FY23 Particulars1 H1'FY22 H1'FY23 Total Revenue from Operations 3,292 3,051 Revenues were Rs 3,051 Crore versus Rs 3,292 Crore in H1'FY22. Reported EBITDA 723 436 Depreciation and Amortisation 188 189 Reported EBITDA at Rs 436 Crore vs. Rs 723 Crore in H1'FY22. EBIT 53
Slide 29: Financial Performance | FY22
Financial Performance | FY22 Particulars1,2 FY21 FY22 YoY (%) Revenue Revenue was Rs 6,130 Crore versus Rs 6,099 Crore in FY21 Pharmaceuticals 5,790 5,651 -2% • Pharmaceuticals revenue at Rs 5,651 Crore as compared to Rs Contract Research and Development Services 305 457 50% 5,790 Crore in FY21 Pr
Slide 30: Appendix
Appendix 30
Slide 31: Income Statement – Q2 & H1’FY23
Income Statement – Q2 & H1’FY23 Particulars1 Q2'FY22 Q2'FY23 YoY (%) H1'FY22 H1'FY23 YoY (%) Revenue from Operations Specialty Pharmaceuticals 651 814 25% 1,282 1,536 20% CDMO Sterile Injectables 409 299 (27%) 782 562 (28%) Generics 333 161 (51%) 765 340 (56%) Contract Research Development and Manuf
Slide 32: For more information
For more information For Investors: For Investors: Siddharth Rangnekar SurajitVineet Pal V Mayer CDR India Ph: +91Ph: +91 120 436120 436 1103 1002 Ph: +91 +91 9769919966 E-mail:E-mail: vineet.mayer@jubl.com Surajit.pal1@jubl.com E-mail: siddharth@cdr-india.com For Media: Clayton Dsouza Sudhakar Safa
Slide 33: Thank You
Thank You Corporate Office 1-A, Sector-16A, Noida-201301, UP, India Email: support@jubl.com 33
Jubilant Pharmova — Investor Presentation (November 2022) on 6ix